Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
ENZN's Cash-to-Debt is ranked higher than
99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. ENZN: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ENZN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22  Med: 9999.5 Max: No Debt
Current: No Debt
Equity-to-Asset 0.97
ENZN's Equity-to-Asset is ranked higher than
89% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ENZN: 0.97 )
Ranked among companies with meaningful Equity-to-Asset only.
ENZN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.17  Med: 0.59 Max: 0.99
Current: 0.97
-0.17
0.99
Interest Coverage No Debt
ENZN's Interest Coverage is ranked higher than
99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ENZN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ENZN' s Interest Coverage Range Over the Past 10 Years
Min: 0.05  Med: 8.55 Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 12.10
WACC vs ROIC
6.79%
-29.77%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 79.22
ENZN's Operating Margin % is ranked higher than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. ENZN: 79.22 )
Ranked among companies with meaningful Operating Margin % only.
ENZN' s Operating Margin % Range Over the Past 10 Years
Min: -34.23  Med: 25.16 Max: 92.36
Current: 79.22
-34.23
92.36
Net Margin % -30.50
ENZN's Net Margin % is ranked higher than
65% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. ENZN: -30.50 )
Ranked among companies with meaningful Net Margin % only.
ENZN' s Net Margin % Range Over the Past 10 Years
Min: -43.19  Med: 22.56 Max: 181.11
Current: -30.5
-43.19
181.11
ROE % -12.02
ENZN's ROE % is ranked higher than
70% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. ENZN: -12.02 )
Ranked among companies with meaningful ROE % only.
ENZN' s ROE % Range Over the Past 10 Years
Min: -12.02  Med: 1.44 Max: 165.21
Current: -12.02
-12.02
165.21
ROA % -11.76
ENZN's ROA % is ranked higher than
71% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. ENZN: -11.76 )
Ranked among companies with meaningful ROA % only.
ENZN' s ROA % Range Over the Past 10 Years
Min: -11.76  Med: 8.87 Max: 136.6
Current: -11.76
-11.76
136.6
ROC (Joel Greenblatt) % 13040.20
ENZN's ROC (Joel Greenblatt) % is ranked higher than
100% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. ENZN: 13040.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ENZN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -76.24  Med: 19.77 Max: 13040.2
Current: 13040.2
-76.24
13040.2
3-Year Revenue Growth Rate -34.60
ENZN's 3-Year Revenue Growth Rate is ranked lower than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ENZN: -34.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ENZN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -40.7  Med: 5.1 Max: 164.3
Current: -34.6
-40.7
164.3
3-Year EBITDA Growth Rate -27.90
ENZN's 3-Year EBITDA Growth Rate is ranked lower than
80% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. ENZN: -27.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ENZN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -55.5  Med: -10.8 Max: 65.5
Current: -27.9
-55.5
65.5
» ENZN's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ENZN Guru Trades in Q1 2016

Paul Tudor Jones 47,998 sh (unchged)
Carl Icahn 5,904,863 sh (unchged)
Jim Simons 3,143,585 sh (-10.22%)
» More
Q2 2016

ENZN Guru Trades in Q2 2016

Paul Tudor Jones 47,998 sh (unchged)
Carl Icahn Sold Out
Jim Simons Sold Out
» More
Q3 2016

ENZN Guru Trades in Q3 2016

Paul Tudor Jones 47,998 sh (unchged)
» More
Q4 2016

ENZN Guru Trades in Q4 2016

Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ENZN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:JAGX, OTCPK:AYTU, OTCPK:AURX, NAS:OGXI, OTCPK:IMMG, OTCPK:NSPDF, NAS:RTTR, OTCPK:WLDFF, OTCPK:MNTM, OTCPK:VRTHF, OTCPK:NMUS, OTCPK:CLCS, NAS:BSTG, OTCPK:LIXT, OTCPK:MYMX, OTCPK:MYMMF, OTCPK:REPCF, OTCPK:ATBPF, OTCPK:CRRTF, NAS:CERC » details
Traded in other countries:EZ1.Germany,
Headquarter Location:USA
Enzon Pharmaceuticals Inc is in the business of receiving royalty revenues from existing licensing agreements with other companies. related to sales of drugs by various companies. It earns revenues from drugs namely, PegIntron, Sylatron, Macugen & CIMZIA.

Enzon develops and manufactures enhanced therapeutics. Its proprietary PEG technology attaches polyethylene glycol polymers to proteins and other pharmaceuticals to enhance their therapeutic value. The company also has developed single-chain, genetically engineered, antigen-binding proteins that target and penetrate tumors more readily than standard antibodies. Enzon produces Adagen, which treats severe combined immunodeficiency disease, and Oncaspar, which treats acute lymphoblastic leukemia. Enzon helped develop PEG-Intron, which is marketed by Schering-Plough.

Top Ranked Articles about Enzon Pharmaceuticals Inc

Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Activist investor continues his interest in penny stock
After selling out in the second quarter, Carl Icahn (Trades, Portfolio) acquired an even larger position in Enzon Pharmaceuticals (ENZN) on Nov. 28. Read more...

Ratios

vs
industry
vs
history
Price-to-Owner-Earnings 3.12
ENZN's Price-to-Owner-Earnings is ranked higher than
94% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. ENZN: 3.12 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ENZN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.32  Med: 3.88 Max: 2064
Current: 3.12
1.32
2064
PB Ratio 0.97
ENZN's PB Ratio is ranked higher than
91% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. ENZN: 0.97 )
Ranked among companies with meaningful PB Ratio only.
ENZN' s PB Ratio Range Over the Past 10 Years
Min: 0.72  Med: 2.15 Max: 13.28
Current: 0.97
0.72
13.28
PS Ratio 1.61
ENZN's PS Ratio is ranked higher than
93% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. ENZN: 1.61 )
Ranked among companies with meaningful PS Ratio only.
ENZN' s PS Ratio Range Over the Past 10 Years
Min: 0.96  Med: 2.22 Max: 12.01
Current: 1.61
0.96
12.01
Price-to-Free-Cash-Flow 2.13
ENZN's Price-to-Free-Cash-Flow is ranked higher than
93% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. ENZN: 2.13 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ENZN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.27  Med: 6.37 Max: 658.46
Current: 2.13
1.27
658.46
Price-to-Operating-Cash-Flow 2.13
ENZN's Price-to-Operating-Cash-Flow is ranked higher than
93% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. ENZN: 2.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ENZN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.27  Med: 6.82 Max: 87.14
Current: 2.13
1.27
87.14
EV-to-EBIT 0.51
ENZN's EV-to-EBIT is ranked higher than
96% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. ENZN: 0.51 )
Ranked among companies with meaningful EV-to-EBIT only.
ENZN' s EV-to-EBIT Range Over the Past 10 Years
Min: -87.6  Med: 2 Max: 142.1
Current: 0.51
-87.6
142.1
EV-to-EBITDA 0.51
ENZN's EV-to-EBITDA is ranked higher than
96% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. ENZN: 0.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
ENZN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -70.5  Med: 3.8 Max: 52
Current: 0.51
-70.5
52
Shiller PE Ratio 0.46
ENZN's Shiller PE Ratio is ranked higher than
94% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. ENZN: 0.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
ENZN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 0.44  Med: 0.81 Max: 1.65
Current: 0.46
0.44
1.65
Current Ratio 25.96
ENZN's Current Ratio is ranked higher than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. ENZN: 25.96 )
Ranked among companies with meaningful Current Ratio only.
ENZN' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 5.44 Max: 80.55
Current: 25.96
0.97
80.55
Quick Ratio 25.96
ENZN's Quick Ratio is ranked higher than
73% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. ENZN: 25.96 )
Ranked among companies with meaningful Quick Ratio only.
ENZN' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 5.06 Max: 80.55
Current: 25.96
0.82
80.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
ENZN's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. ENZN: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ENZN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -23.4  Med: -5.3 Max: 9.2
Current: -0.1
-23.4
9.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.33
ENZN's Price-to-Net-Cash is ranked higher than
92% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. ENZN: 1.33 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ENZN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 13.21 Max: 344
Current: 1.33
0
344
Price-to-Net-Current-Asset-Value 1.33
ENZN's Price-to-Net-Current-Asset-Value is ranked higher than
92% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. ENZN: 1.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ENZN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 9.67 Max: 269
Current: 1.33
0
269
Price-to-Tangible-Book 0.96
ENZN's Price-to-Tangible-Book is ranked higher than
94% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. ENZN: 0.96 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ENZN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 7.21 Max: 412.5
Current: 0.96
0.76
412.5
Price-to-Intrinsic-Value-Projected-FCF 0.10
ENZN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
99% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. ENZN: 0.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ENZN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.3 Max: 45.52
Current: 0.1
0
45.52
Price-to-Median-PS-Value 0.73
ENZN's Price-to-Median-PS-Value is ranked higher than
77% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. ENZN: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ENZN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 2.86 Max: 100
Current: 0.73
0
100
Earnings Yield (Greenblatt) % 199.84
ENZN's Earnings Yield (Greenblatt) % is ranked higher than
98% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. ENZN: 199.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ENZN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.7  Med: 12.5 Max: 401.6
Current: 199.84
0.7
401.6

More Statistics

Revenue (TTM) (Mil) $6.55
EPS (TTM) $ -0.06
Beta0.76
Short Percentage of Float0.41%
52-Week Range $0.22 - 0.50
Shares Outstanding (Mil)44.21
» More Articles for ENZN

Headlines

Articles On GuruFocus.com
Carl Icahn Discloses 20 Million Share Stake in Xerox Spinoff Conduent Jan 10 2017 
Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Dec 02 2016 
Top Micro-Cap Picks From the Gurus Jun 23 2015 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
GuruFocus Real Time Picks of the Week Jan 10 2014 
Seth Klarman Buys New Stock Kindred Biosciences, Cut Stake in Enzon Jan 10 2014 
Billionaires Hold Bargains, 40% Off or More Sep 11 2013 
Charles Brandes Top Second Quarter Portfolio Changes Aug 09 2013 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Enzon Inc. Reports Operating Results (10-K) Mar 16 2011 

More From Other Websites
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 18, 2017 May 18 2017
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 28, 2017 Mar 28 2017
Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Dec 02 2016
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 Aug 12 2016
OTC Markets Group Welcomes Enzon Pharmaceuticals, Inc. to OTCQX Aug 09 2016
Enzon Pharmaceuticals, Inc. :ENZN-US: Earnings Analysis: 2015 By the Numbers Mar 24 2016
Enzon Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 10 2015
Guidance & Quarterly Review on Four Biotech Companies Aug 14 2015
Enzon Pharmaceuticals Inc (ENZN)’s Shares Rally After Special Cash Dividend Announcement Jul 06 2015
Voltari Corp (VLTC): Carl Icahn Stirring Yet Another Pot Apr 01 2015
DELiA*s Rebounds As Reports Suggest Delisting May Be Imminent Nov 03 2014
George Soros Picks KIOR, RSH, BIOL Soar On Monday Sep 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)